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Background: We designed a telemonitoring strategy for teenagers with inflammatory bowel disease to prevent an anticipated
disease flare and avert unplanned office visits and day care procedures. The strategy was evaluated in a randomized controlled
trial that involved 11 Dutch pediatric gastroenterology centers, each using repeated symptom scores and stool calprotectin
measurements. In the telemonitoring arm of the trial, teenagers (n=84) as well as their health providers were alerted to out-of-range
results, and suggestions for change in therapy were offered. We demonstrated that the technology was a safe and cost saving
alternative to health checks by the specialist at fixed intervals.
Objective: The aim of this study was to evaluate whether we could move our telemonitoring strategy from a demonstration
project to one that is sustained within existing sites.
Methods: In this empirical case study, we used the nonadoption, abandonment, scale-up, spread, and sustainability (NASSS)
framework to explore the challenges to implementing our strategy. The framework distinguishes 7 domains: (1) the illness, (2)
the technology, (3) the value proposition, (4) the adopter system, (5) the organization, (6) the societal system, and (7) the time
dimension. We summarized the challenges across all 7 domains and classified them as simple (+++), complicated (++), or complex
(+). Technologies in which multiple domains are complicated have proven difficult to implement, whereas those with multiple
complex domains may not even become mainstreamed.
Results: The technology that we used and the linked program (IBD-live) allowed us to select and target the teenagers who were
most likely to benefit from a face-to-face encounter with their specialist (+++). The value proposition of the technology was clear,
with a distinct benefit for patients and an affordable service model, but health providers had plausible personal reasons to resist
(double data entry, ++). The organization was not yet ready for the innovation, as it requires a shift to new ways of working (+).
We had no concerns about reimbursement, as Dutch health insurers agreed that screen-to-screen consultations will be reimbursed
at a rate equivalent to face-to-face consultations (+++). Finally, the technology was considered easy to adapt and evolve over
time to meet the needs of its users (+++).
Conclusions: The challenges to be addressed are merely complicated (++) rather than complex (+), which means that our program
may be difficult but not impossible to sustain within existing sites. After integrating the technology and its use with local workflows
first, we believe that our telemonitoring strategy will be ready for sustained adoption. In contrast with what we did ourselves, we
recommend others to use the NASSS framework prospectively and in real time to predict and explore the challenges to implementing
new technologies.
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Introduction
Crohn's disease and ulcerative colitis are the 2 main forms of
inflammatory bowel disease (IBD). Both are chronic lifelong
conditions that cause intestinal inflammation. The inflammation
waxes and wanes over time in a seemingly unpredictable
fashion. The prevalence of IBD exceeds 0.3% in North America,
Oceania, and many countries in Europe [1]. A third of patients
experience at least one flare per year, which is associated with
pain, disruption of normal activities, and reduction of quality
of life [2].
Follow-up of patients with IBD traditionally comprises
scheduled visits regardless of how well the patients feel. For
every scheduled visit that is instrumental in preventing
unnecessary pain or disability, many more will be uninformative.
Selecting and targeting the patients who are most likely to
benefit from a face-to-face encounter with their specialist are
logical solutions.
We have recently shown that repeated quantitative measurements
of fecal calprotectin help specialists and patients recognize
disease flares at an early stage [3]. Monitoring calprotectin
values longitudinally enables timely adjustment of therapy plans.
In modern-day IBD care, the treatment target is to keep
calprotectin values below 250 μg/g, which is the equivalent of
disease remission [4]. When calprotectin values exceed this
critical threshold, the patient has a high risk of disease flare and
treatment intensification is justified. Conversely, when
calprotectin values drop again below the critical threshold,
induction therapy can be safely tapered down.
Although it seems that without monitoring, patients with IBD
would not be in a position to receive optimal care, there are
several potential difficulties and unresolved matters that relate
to the use of calprotectin. It may disrupt doctor-patient
communication, unduly focusing attention on inflammatory
markers (medicalization and creating worried well), increase
health care costs, and bears the risk of overdiagnosing flares as
calprotectin may also rise in bacterial gastrointestinal infections.
Between June 2013 and January 2016, we conducted a
randomized controlled trial (RCT) comparing a Web-based
telemonitoring strategy for teenagers with IBD (IBD-live,
designed for early detection of relapse) and conventional
follow-up [5]. We concluded that patients in the telemonitoring
group followed a similar disease course as those in conventional
follow-up, although they had significantly less face-to-face
encounters with their specialist. Moreover, the number of times
blood was taken, trips to the hospital, and hours of absence from
school or social activities were lower in the telemonitoring
group. The majority of patients assigned to the telemonitoring
arm took an active interest in their readings, engaged
enthusiastically with the feedback, and found this technical
innovation reassuring. In a patient satisfaction survey that was
performed after the close-out visit (after 52 weeks of
participation), the majority of respondents agreed that
telemonitoring was time saving, increased their understanding
of the disease, and did not disturb them. Overall, 81% of
respondents wished to use the telemonitoring services in future.
We sought to evaluate whether we could move our
telemonitoring strategy from a demonstration project to one that
is sustained within existing sites.
Methods
Context
The Web-based telemonitoring strategy was tested in 11
pediatric gastroenterology practices, which were recruited on
the basis of their interest in IBD. The principal investigators at
the various sites were pediatric gastroenterologist and members
of the Kids with Crohn’s and Colitis working group for
Collaborative Research in the Netherlands. Together they treat
about two-thirds of the total pediatric IBD population in the
Netherlands. National treatment guidelines provided uniformity
in treatment among practices [6]. Table 1 summarizes practice
characteristics for the 11 sites.
Outline of the Telemonitoring Strategy
Patients in the telemonitoring group had access to the IBD-live
website, a cloud-based portal with 3 modules, as follows: (1)
the Flarometer, an automatic cumulation of patient-rated
symptom scores and fecal calprotectin measurements, (2) a
platform for direct communication with the local IBD team with
guaranteed feedback within 2 working days, and (3) a module
with study questionnaires (on quality of life, absenteeism, and
health care utilization). Patients could freely explore the website,
but the majority only accessed it after receiving an email
notification that it was time for the next Flarometer measurement
(Figure 1). In case the Flarometer was not used despite 3 email
notifications with 7-day intervals, the IBD-nurse or specialist
phoned the patients to encourage them to fill in the Flarometer
and send in a stool sample. The email notification had a link
that took the user in a few steps in sequential order to the
Flarometer (tunnel design) [7]. The Flarometer strategy is
presented in Figure 2. Patients as well as their specialists were
alerted to out-of-range results, and suggestions for change in
therapy were offered.
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Table 1. Practice characteristics (N=11).
Number of practices, nCharacteristics
Practice type
6Tertiary care hospital
5Large regional general hospital
Practice size
710 to 100 pediatric IBDa patients
4More than 100 pediatric IBD patients
Adolescents transitioned to adult-oriented care
7More than 10 per year
4≥10 per year
Pediatric IBD nurse present
8Yes
3No
Pediatric endoscopy unit available
11Yes
0No
aIBD: Inflammatory bowel disease.
Figure 1. Swim lane process diagram showing the sequence of events from sending an automated reminder by email to the advice on treatment and
timing of re-measurement. The parallel lines divide the diagram into lanes, with one lane for each person or subprocess. The horizontal direction
represents the sequence of events in the overall process. Arrows between the lanes represent how information or material is passed among the subprocesses.
Black arrows represent the ideal flow; gray dotted arrows represent the weakest links in the chain of events. IBD: inflammatory bowel disease.
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Figure 2. Flarometer strategy. Algorithm with advice on treatment and the timing of re-measurement (figure printed with permission from Heida et al
[5]). PUCAI: pediatric ulcerative colitis activity index; PCDAI: pediatric Crohn's disease activity index.
Evaluation
During the RCT, we gathered information on its potential for
implementation in a real-world setting. Data sources included
study parameters as specified in the study protocol [8] and ethics
paperwork, the log of technical failures, and 1 additional
semistructured interview for all patient participants. In addition,
for the purpose of this case study, we collected information
from 5 research staff including the principal investigator (PFvR)
and 2 research coordinators (AD and AH), 13 clinical staff
involved in the trial, 4 clinical staff not involved in the trial, 2
hospital decision makers, and 1 Web designer. This information
was extracted from 15 semistructured and 4 narrative interviews.
We used the recently published nonadoption, abandonment,
scale-up, spread, and sustainability (NASSS) framework to
systematically explore the challenges and decide whether we
should abandon our telehealth technology or aim to achieve
sustained adoption within the existing sites [9].
The NASSS framework comprises measures categorized in 7
domains: (1) the illness, (2) the technology, (3) the value
proposition, (4) the adopter system (professional staff, patients,
and lay carers), (5) the organization, (6) the wider (institutional
and societal) system, and (7) interaction and mutual adaptation
among all these domains over time. In Table 2, we summarize
all the original measures and how we translated them to assess
local applicability. All measures were classified as simple
(straightforward, predictable, and few components—as in
making a sandwich), complicated (remains predictable, but with
multiple interacting components or issues—as in building a
rocket), or complex (dynamic, unpredictable, and not easily
disaggregated into constituent components—as in raising a
child). The choice for 1 of 3 classes was further substantiated
by tabulated examples in the NASSS index paper [9].
Technologies in which multiple domains are complicated have
proven difficult, slow, and expensive to implement. Those in
which multiple domains are complex may not even become
mainstreamed.
Overall, 2 assessors (AD, PFvR) independently rated the
measures with the use of a predefined matrix. Disagreements
were resolved by discussion and, if necessary, a third
independent assessor (AH).
Ethical Considerations
The patient-related data in this paper as well as the log of
technical failures were collected as part of the initial RCT. The
Medical Ethical Committee of the University Medical Centre
Groningen approved the study protocol (METC 2013/010).
Secondary approval was obtained from all participating centers.
Use of additional data collected from nonpatient participants
(including semistructured interviews with specialists and IBD
nurses and qualitative interviews with managers and Web
designer) in this empirical case study did not require approval
according to the Dutch Medical Research Involving Human
Subject Act.
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Table 2. Overview of the nonadoption, abandonment, scale-up, spread, and sustainability (NASSS) framework used to evaluate the success of the
IBD-live telemonitoring strategy. The left column shows the original NASSS questions, the right column shows how we adapted some to assess local
applicability.
Adapted questionsDomain and questions
Domain 1: The illness
How well does the Flarometer strategy predict out-of-range or all-is-well
events?
1A. What is the nature of the condition or illness? 
What are the sociocultural factors associated with good adherence to the
technology? (Original RCTa)b
1B. What are the relevant sociocultural factors and comorbidities? 
Domain 2: The technology
No changes2A. What are the key features of the technology? 
No changes2B. What kind of knowledge does the technology bring into play? 
No changes2C. What knowledge and/or support is required to use the technology? 
No changes2D. What is the technology supply model? 
Domain 3: The value proposition
No changes3A. What is the developer’s business case for the technology (supply-
side value)?
 
What is the change from baseline in quality-of-life and cost-effectiveness?
(Original RCT)b
3B. What is the desirability, efficacy, safety, and cost effectiveness
of the technology (demand-side value)?
 
Domain 4: The adopter system
No changes4A. What changes in staff roles, practices, and identities are implied? 
No changes4B. What is expected of the patient (and/or immediate caregiver)—is
this achievable by, and acceptable to, them?
 
Not applicable4C. What is assumed about the extended network of lay caregivers? 
Domain 5: The organization
No changes5A. What is the organization’s capacity to innovate? 
No changes5B. How ready is the organization for this technology-supported
change?
 
No changes5C. How easy will the adoption and funding decision be? 
No changes5D. What changes will be needed in team interactions and routines? 
No changes5E. What work is involved in implementation and who will do it? 
 Domain 6: The wider context
No changes6A. What is the political, economic, regulatory, professional (eg,
medicolegal), and sociocultural context for program rollout?
 
Domain 7: The time dimension
No changes7A. How much scope is there for adapting and coevolving the tech-
nology and the service over time?
 
No changes7B. How resilient is the organization to handling critical events and
adapting to unforeseen eventualities?
 
aRCT: randomized controlled trial.
bWe already published the results of this measure in the original RCT [5].
Results
A summary of the challenges of the IBD-live telemonitoring
strategy per domain is given in Table 3.
In the following sections, we give a detailed overview of the
considerations we have made during the rating process.
Domain 1: The Illness
Patients were followed for 52 weeks. During this observation
period, 448 Flarometer scores were generated, of which 176
(39.3%) were in the green stratum, 181 (40.4%) were in the
orange stratum, and 91 (20.3%) were in the red stratum. Overall,
30 of 176 green all-is-well results were generated during a
close-out visit and were excluded from analysis. The median
change in fecal calprotectin concentration in the follow-up stool
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of the 146 remaining cases was 0 (interquartile range, IQR 0-70)
ug/g (Multimedia Appendix 1). A total of 11 of 91 red
out-of-range alerts were generated during a close-out visit and
were excluded from analysis for not leading to a response from
patient or health provider anymore. Among the remaining 80
red alerts were the patients who were most likely to benefit from
an encounter with their specialist because of an imminent flare.
In 39 of 80 cases, the local IBD team followed the automated
advice to intensify treatment. The median change in fecal
calprotectin concentration in the follow-up stool in this group
was −255 (IQR −975 to 20) ug/g. In 21 of 80 cases, there was
a well-founded reason to deviate from the treatment advice and
follow a watchful waiting strategy. These reasons included the
presence of colon pathogens and high symptom scores caused
by disorders that were not related to IBD such as irritable bowel
syndrome. In these cases, the median change in fecal calprotectin
concentration in the follow-up stool was −216 (IQR −1965 to
0) ug/g. In 20 of 80 red alerts, there was no contact between
patient and health provider, despite 3 email notifications and
an attempt to contact the patient by telephone after 2 weeks of
passivity. This strategy violation led to a median change in fecal
calprotectin concentration of 167 (IQR 0-1047) ug/g. Multimedia
Appendix 1 shows that the direction of change in calprotectin
concentration in the latter group was different from the others
and toward further deterioration.
The foregoing made us decide that ad hoc face-to-face follow-up
consultations were fairly predictable and consistent in the group
with out-of-range results. We had few unpredictable
eventualities in the all-is-well results. Both disease relapses and
sustained remissions were predictable, and the treatment advice
generated by the Flarometer was reliable. This measure was
therefore classified as simple.
Domain 2: The Technology
The telemonitoring strategy relied on calprotectin measurements
in stool samples that were sent to the hospital laboratory by
ordinary mail. Immediately after arrival, the stool sample was
analyzed with a point-of-care test that offers quantitative results
within minutes. This rapid test has good agreement with the
established enzyme-linked immunosorbent assay (ELISA) and
can therefore serve as a reliable alternative to the
time-consuming ELISA in the follow-up of patients with IBD
[10]. We plotted the calprotectin results per patient over time
to give both patient and doctor an overview of the inflammatory
state of the gut during the experiment. Patients found the
longitudinal tracking of calprotectin results helpful and trusted
the results. However, doctors were equivocal about whether a
rise in calprotectin above 250 ug/g was sufficient to justify
treatment intensification. Some wished to perform additional
diagnostic tests to rule out gastrointestinal infections before
progressing to a treatment decision. Multimedia Appendix 2
shows that concurrent gastrointestinal infections were found in
14% of stools with out-of-range results, and this proportion was
not statistically different from stools with calprotectin values
in the target range (below 250 ug/g).
Use of the telemonitoring strategy required no previous
knowledge from the patients except for recognition of what
conditions count as urgent, such as a drug reaction. All measures
within this domain were classified as simple, with the exception
of 2D: the sequence of events from sending an automated
reminder by email to the formulation of a treatment advice
(Figure 1), relying on a bespoke solution from a small-sized
enterprise, which carries a risk of supplier withdrawal. However,
its relatively substitutability is relatively straightforward, and
the complexity of this measure was therefore classified as
complicated.
Domain 3: The Value Proposition
Our telemonitoring strategy depended on a predictive algorithm
on the basis of calprotectin changes over time to prevent an
anticipated disease flare and avert unplanned outpatient visits
and day care procedures (including colonoscopies). Although
the technology created new possibilities for personalized
medicine, such as selecting and targeting the patients who are
most likely to benefit from a face-to-face encounter with their
specialist, we did not observe a reduction in workload. Patients
assigned to the telemonitoring group had fewer face-to-face
encounters with the IBD team compared with those in
conventional follow-up, but the number of telecontacts (emails
and telephone calls) increased by 40%. The telemonitoring
strategy was cost effective, as it demonstrated comparable
effectiveness with conventional follow-up at lower costs. In the
intention-to-treat analysis, telemonitoring led to a mean annual
cost saving of €89 per patient, and this amount increased to
€360 in those who were adherent to the technology. The
time-saving aspect of the technology and the better sense of
disease control were highly valued by patients and their
caretakers. Not all patients were suitable to be followed in a
telemonitoring program. It is important to realize that differences
exist in people’s desire for information. Some patients seek as
much information as possible about the threat of a disease flare
(monitors), whereas others try to avoid potentially threatening
information (blunters) [11]. The Flarometer technology will
give the former category of patients and parents a greater sense
of control, as opposed to the latter category who may feel more
vulnerable because of the constant confrontation with their
chronic disease. This aspect may partially explain attrition in
the telemonitoring arm.
We are not sure that use of the telemonitoring strategy reduces
the demand on health services, but it certainly allows selecting
and targeting the patients who are most likely to benefit from
a face-to-face encounter with their specialist. Furthermore, the
business case is still underdeveloped. We therefore classified
measure 3A as complicated. However, the technology itself is
desirable for patients, and it is safe and cost effective,
particularly in those who are adherent to the telemonitoring
strategy, and measure 3B was therefore classified as simple.
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Table 3. Summary of the challenges of the IBD-live telemonitoring strategy based on the nonadoption, abandonment, scale-up, spread, and sustainability
framework.
ExplanationRatingaDomain and question
Domain 1: The illness
Ad hoc face-to-face follow-up consultations were fairly predictable and
consistent in the group with out-of-range results; few unpredictable
eventualities in the all-is-well results.
+++1A. How well does the Flarometer strategy predict out-of-
range or all-is-well events?
Majority of teenage patients were considered suitable for the technology,
except for those with concurrent diseases such as arthritis and sclerosing
+++1B. What are the sociocultural factors associated with good
adherence to the technology?
cholangitis; Patients with delayed emotional maturity, prominent func-
tional gastrointestinal disease, or with little knowledge of the Dutch
language were considered less suitable for the technology.
Domain 2: The technology
Access to Web-based portal was easy via a link in the email notification.
The tunnel design (Figure 1) guided the patients in a few steps in sequen-
+++2A. Perceived usability
tial order through the Flarometer. Successful stool-based monitoring
system for teenagers heavily relies on active and coordinating role of the
parent.
Treatment advice was accepted and trusted by patients. Concurrent gas-
trointestinal infection was found to be the cause of the out-of-range result
in a minority of cases.
+++2B. Appropriateness of the automated treatment advice
Use of the technology requires no previous knowledge from the patient,
except for recognizing what conditions count as urgent.
+++2C. Knowledge and/or support required to use the technol-
ogy
Technology relies on bespoke solution from a small-sized enterprise with
risk of supplier withdrawal.
++2D. Technology supply model
Domain 3: The value proposition
Not sure that use of the technology reduces the demand on health services,
but it certainly allows selecting and targeting the patients who are most
likely to benefit from a face-to-face encounter with their specialist.
++3A. Developer’s business case for the technology (supply-
side value)
Technology is desirable for patients, it is safe and cost effective, particu-
larly in those who are adherent to the telemonitoring strategy.
+++3B. Efficacy, safety, and cost-effectiveness of the technol-
ogy (demand-side value)
Domain 4: The adopter system
Difference between innovators and early adopters (who embraced the
technology) on 1 side and a minority of other health providers (who were
+++4A. Implications for staff roles, practices, and identities in
case of adoption
reluctant to adopt the technology). Technology was not seen as a threat
to job security.
Patients were already familiar with the stool collection procedure. Log-
ging on to the system was easy. The study presupposed that parents or
+++4B. What is expected of the patient (and/or immediate
caregiver)—and is this achievable by, and acceptable to,
them? carers were actively supporting their child during the study observation
period.
Domain 5: The organization
Technology follows the natural work flow but conflicts with established
hospital electronic databases and therefore requires double data entry.
This will put a strain on the already overstretched health service.
+5A. Organization’s capacity to innovate
No linked routine for booking face-to-face appointments in case of a red
alert.
++5B. Readiness for this technology-supported change
Anticipated reduction in costs were not realized as case management
was not always successful in avoiding follow-up consultations and day
care admissions. Neutral cost-benefit balance.
++5C. Easiness of adoption and funding
Variation in clinician engagement was based on the vision of local teams
of whether remote biomarker monitoring enhances rather than threatens
the existing service. Expansion of rapid access possibilities is required.
++5D. Changes required in team interactions and routines
Significant work needed to build shared vision, engage staff, enact new
practices, and monitor impact.
+5E. Work and persons involved in implementation
Domain 6: The wider context
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Effect of January 2018, the Dutch Health care Authority has agreed that
screen-to-screen consultations will be reimbursed at a rate equivalent to
face-to-face consultations, provided that a substantive report is added to
the patient’s medical record.
+++6A. Political, economic, regulatory, professional, and so-
ciocultural context for program rollout
Domain 7: The time dimension
The technology can easily be adapted over time.++7A. Scope for adapting and coevolving the technology over
time
The research head quarter and the Web designer were able to detect
critical events quickly and respond to these through coordinated action.
+++7B. Handling critical events and adaptation to unforeseen
eventualities
aRating: Simple +++; Complicated ++; Complex +.
Domain 4: The Adopter System
The structured questionnaire that was spread among health
providers after termination of the RCT revealed the difference
between innovators and early adopters (who embraced the
technology) on 1 side and a minority of other health providers
who were reluctant to adopt the technology on the other. The
hurdle was not learning to use a new technology but rather the
prospect of double data entry when running a telemonitoring
service in parallel with conventional follow-up. This perception
of overload will put a strain on already overstretched health
services. The telemonitoring strategy was not seen as a threat
to job security, although a considerable proportion of health
providers felt that it changed the professional distance to their
patients (Figure 3).
For patients, the easiest way to log on to our system was via a
link in the email notification. Some patients forgot their
username or password, and the time involved in recovering their
username or resetting their account password demoralized them.
The tunnel design guided the patients in a few steps in sequential
order through the Flarometer, and entering data was merely
clicking in a data entry form. The patients were already familiar
with the stool collection process with its inherent obstacles [12].
As neither existing staff nor patients and caregivers had to learn
new skills, we classified all measures within this domain as
simple.
Domain 5: The Organization
Decision makers may be disappointed to read that cost-savings
by the use of telemonitoring were only modest, but
physician-nurse task shifting, on the other hand, appeals greatly
to health decision makers. As the technology allows to select
and target patients who benefit from a face-to-face encounter
with their physician at short notice for timely adjustment of
therapy plans, nurse specialists in IBD treatment teams may
dedicate their time to other problems, including repeat
prescriptions, quality-of-life issues, and absenteeism from school
or work, not to mention that time will be needed to motivate
patients who ignored automated reminders. Successfully
accomplishing a task shift probably involves the expansion of
the number of rapid access clinic consultation slots. In addition,
currently, there is no built-in routine for booking rapid
consultations in case of out-of-range results. Although the
telemonitoring strategy follows the natural work flow, it
conflicts with established hospital electronic databases and
therefore requires double data entry. This will put a strain on
already overstretched health services. To reduce double
documentation, clinicians may want to import data from
electronic health records into the cloud-based telemonitoring
system or vice versa. This is currently not possible. The
organization was perceived as the most problematic of all
domains. We classified measures 5A and 5E as complex. The
last question in domain 5 concerns the work involved in
implementation. We regret to say that such a study is extensive
and often hidden, and we typically underestimated it at the
planning stage. Measures 5B to 5D were classified as
complicated.
Domain 6: The Wider Context
The most significant system-level challenge at the time that we
performed our study was the absence of an established national
tariff for reimbursing electronic health consultations. In the
meantime, the Dutch Health care Authority agreed that with
effect from January 2018, screen-to-screen consultations are
reimbursed at a rate equivalent to face-to-face consultations,
provided a substantive report is added to the patient’s medical
record [13]. Reimbursement is only possible when the
screen-to-screen consultation is really comparable in both
content and duration with a regular face-to-face consultation at
the clinic. Second, the screen-to-screen contact should be booked
in advance. As financial and regulatory requirements are now
in place nationally, we classified this measure as simple.
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Figure 3. Health provider’s opinions about home telemonitoring (n=15). The proportion of respondents who agreed to the statements (left of the neutral
line) versus those who disagreed (right of the neutral line). IBD: inflammatory bowel disease.
Domain 7: The Time Dimension
We used email notifications to communicate with the target
population, but teenagers hardly use this ancient form of digital
communication anymore. Despite being an over 40-year-old
technology, email has many advantages to newer ways of
communication such as WhatsApp, and it is still considered a
more trustful way of communication. Email is persistent, easily
searchable, one is able to send it from virtually every
internet-able device in the world, it uses small data volume, one
can attach whatever is wanted, and it is expandable (adding
encryption or signing for instance). Having said all this, better,
safer, and more appealing tools for communication in health
care are a good thing. It will be interesting to see what swoops
in to fill the gaps for patient-related data exchange in health
care.
As the potential for adapting and coevolving the technology
and service over time is uncertain, we classified this measure
as complicated. With the technology that we used during the
RCT, the research head quarter and the Web designer were able
to detect critical events quickly and responded to these through




We recently reported on a telemonitoring strategy for teenagers
with IBD (IBD-live) that was designed for early detection of
relapse and follow-up of appropriateness of treatment. We
concluded that the technology was a safe and cost-saving
alternative to conventional follow-up. For patients and parents
in the intervention arm, the time-saving aspect and the better
sense of disease control were highly valued. In this empirical
case study, we used the newly developed NASSS framework
to explore the challenges to implementing the IBD-live strategy
and decide whether we should abandon this technology or
sustain it within existing sites [9]. The framework allowed us
to explore complexity in multiple interacting domains. Aspects
of the different domains were classified as simple (+++:
straightforward, predictable, and with few components—as in
making a sandwich), complicated (++: predictable, but with
multiple interacting components or issues—as in building a
rocket), or complex (+: dynamic, unpredictable, and not easily
disaggregated into constituent components—as in raising a
child). Our technology-supported telemonitoring strategy was
designed to recognize and manage disease flares at a distance,
and following the treatment advice of the Flarometer led to
similar patient outcomes as the doctor’s advice. This observation
led to the conclusion that the condition that we aim to monitor
(domain 1) is well characterized, well understood, and
predictable (in other words, simple). The technology that we
used (domain 2) was user-friendly for both patients and doctors,
but a minority of health providers did not trust the treatment
advice generated by the Flarometer. As colon pathogens were
only occasionally detected in the stool samples with out-of-range
results, we feel that their apprehension may not be well founded.
The Flarometer algorithm relied on a bespoke solution from a
small-sized enterprise, which always carries a risk of supplier
withdrawal. However, its substitutability is relatively
straightforward, and this aspect of the technology was therefore
classified as complicated. For patients, parents, and health
providers, the value of telemonitoring (domain 3) is in the
possibility for personalized medicine, such as selecting and
targeting the patients who are most likely to benefit from a
face-to-face encounter with their specialist. Access to care was
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improved in those patients who completed the Flarometer from
their home with a result in the low-risk stratum and were
reassured without missing school or work, whereas those with
an out-of-range result were triaged by an IBD nurse for a
physical office visit. However, in a busy, appointment-based
practice, scheduling an urgent patient can be a challenge.
Organizations that wish to use the telemonitoring strategy to
the fullest may want to think of a flexible system to cater for
urgent patients, for example, by expanding the number of rapid
access clinic consultation slots. The supply-side value was
therefore not merely classified as simple but rather as
complicated.
The greatest challenge to scale-up, spread, and sustain our
telemonitoring strategy is, without a doubt, the organization’s
capacity (domain 5) to build the new technology into this
workflow, for example, by automating the steps for booking
office visits in case of suspected disease flares.
Particular Strengths and Limitations of the Project
The main strength of our telemonitoring project was its
randomized and pragmatic design. A heterogeneous group of
patients, parents, health providers, and clinical practices were
included to maximize the applicability of the results to everyday
practice. IBD-live was developed through close collaboration
among developers, clinicians, and representatives of the Dutch
Crohn’s and Colitis patient organization (CCUVN). The director
of the CCUVN was consulted at the inception stage of the
project and was also on the committee of reviewers who decided
on the ZonMw funding.
However, this empirical case study shows that a sturdy evidence
base for the efficacy of the intervention does not guarantee a
spontaneous movement of the intervention into routine clinical
usage. Historically, this research-to-practice gap has not been
the concern of academic clinical researchers [14]. We used the
NASSS framework retrospectively and were only able to explain
why we failed to implement telemonitoring in our daily clinic
till now. If we would have used the framework at an early stage
of our telemonitoring program development, it would have
saved us precious time. In the future, we will definitely use this
framework prospectively and in real time to support new
programs, and we also encourage others to do so. This case
study hinges on the rating of challenges summarized in Table
3. Although 2 assessors (AD and PFvR) independently used a
rating matrix, the generalizability of our findings is problematic.
There is a great deal of subjectivity in how the challenges were
rated, which may have affected the conclusions of this paper.
Comparison With Other Studies
In contrast with our telemonitoring strategy that is not yet
mainstreamed, we know of 1 Dutch IBD telemonitoring
initiative that has been successfully implemented—myIBDcoach
[15,16]. This telemedicine system monitors and registers disease
activity in patients with all subtypes of IBD as well as
patient-reported outcome measures and quality metrics. We
have tried to comprehend why this initiative, which focuses on
adult patients with IBD, has a broad support and is expanding
to both academic and nonacademic IBD centers. The most
important difference with our own project relates to the
institution of a foundation to facilitate implementation and to
improve cooperation among the various stakeholders. The
director of the Dutch IBD patients’ organization, 2
gastroenterologists, an accountant, and an assistant professor
of health analytics systems constitute the board. Representatives
of the IBD section of the Dutch Association for
Gastroenterology, the Dutch Association for Gastroenterologists,
and the Association of IBD Nurse Specialists form a separate
committee which decides on the design and content of
myIBDcoach.
Several other telemonitoring initiatives in IBD care, with direct
connection to the IBD specialist team, have been developed in
Denmark, United States, and the United Kingdom [17-21].
However, in spite of the promising results in the field of
responsive and cost-effective care, these initiatives are all in the
stage of sustained adoption and none are ready for distant spread.
Interpretation
This case study illustrates that our system with remote biomarker
monitoring enhances rather than threatens the existing hospital
service with periodic office visits. Home telemonitoring is
attractive for teenagers and their families, and health
professionals may be interested in using it to keep teenagers
who are well out of hospital and ease the pressure on
overstretched outpatient services. The telemonitoring system is
ideally run with IBD nurses to provide full coverage during
working hours. Patients with disease in remission may have up
to 4 Flarometer measures in 1 year and 1 routine physical office
visit. Patients with an anticipated disease flare will be booked
in between for a rapid access clinic consultation. Patients who
require periodic day care infusions with antitumor necrosis
factor (TNF) monoclonal antibodies may not profit from the
telemonitoring service as they will already have unavoidable
frequent contact with health care providers. However, those on
injectable anti-TNFs, may also highly value our telemonitoring
strategy. Home telemonitoring can move IBD care into a new
era in which teenagers take ownership of their chronic disease
and participate in the therapeutic decision-making process on
the basis of longitudinal tracking of Flarometer results. It is
important to realize that a wide range of services should be
available, as patients and their families have different needs
related to both disease activity and personal circumstances.
Individual needs also change over time, which require a flexible
contact to the hospital.
Abandon or Ready for Sustained Adoption?
Application of the NASSS framework has shown what issues
will be mission-critical to move our telemonitoring strategy
from a demonstration project to one that is fully mainstreamed
and part of business as usual locally. The challenges to be
addressed are merely complicated (++, ie, predictable and
controllable) rather than complex (+), which means that our
program may be difficult but not impossible to sustain within
existing sites.
On the basis of the NASSS framework, we conclude the
following:
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• The technology and linked program were designed around
a well predictable condition (disease flare) in patients with
IBD.
• The prototype of the technology was sufficiently tested in
an RCT.
• The value proposition of the technology was clear, with a
distinct benefit for patients and an affordable service model.
• Health providers have plausible personal reasons to resist
(double data entry).
• The organization may not be ready for the innovation, as
it requires a shift to new ways of working.
• The concerns about reimbursement are not valid reasons to
stall the mainstreaming of the technology.
• The technology is able to adapt and evolve over time in a
way that continues to meet the needs of its users.
After integrating the technology and its use with local
workflows, we believe that our telemonitoring strategy will be
ready for distant spread and long-term sustainability.
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Multimedia Appendix 1
Median (inter quartile range, IQR) change in fecal calprotectin. The time interval after a green all-is-well result and a red
out-of-range alert was 4 and 2 months respectively. A positive value represents an increase in fecal calprotectin.
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Multimedia Appendix 2
Presence of colon pathogens in stool samples as per flarometer color code.
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